

3. Baltieri L, Chaim EA, Chaim FDM, Utrini MP, Gestic MA, Cazzo E. Correlation between nonalcoholic fatty liver disease features and levels of adipokines and inflammatory cytokines among morbidly obese individuals. *Arq Gastroenterol.* 2018; 55(3): 247-51. PMID: 30540086. doi: 10.1590/S0004-2803.201800000-62
4. Bellizzi V, Cupisti A, Locatelli F, Bolasco P, Brunori G, Cancarini G, et al. "Conservative Treatment of CKD" study group of the Italian Society of Nephrology. Low-protein diets for chronic kidney disease patients: the Italian experience. *BMC Nephrol.* 2016; 17(1): 77. PMID: 27401096. PMCID: PMC4939662. doi: 10.1186/s12882-016-0280-0
5. Grander C, Grabherr F, Moschen AR, Tilg H. Non-alcoholic fatty liver disease: Cause or effect of metabolic syndrome. *Visc Med.* 2016; 32(5): 329-34. PMID: 27921044. PMCID: PMC5122994. DOI: 10.1159/000448940
6. Gray SP, Di Marco E, Okabe J, Szyndralewicz C, Heitz F, Montezano AC, et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. *Circulation.* 2013; 127 (18): 1888-902. PMID: 23564668. doi: 10.1161/CIRCULATIONAHA.112.132159
7. Khukhlina OS, Antoniv AA, Dudka IV, Dudka T, Mandryk O. Peculiarities of the clinical course of non-alcoholic steatohepatitis against the background of the chronic kidney disease of the I-III stage with secondary arterial hypertension. *Georgian Medical News.* 2017; 9(270): 59-65. PMID: 28972485
8. Khukhlina OS, Antoniv AA, Kanovska LV, Mandryk O, Smandych V. The effectiveness of non-alcoholic steatohepatitis correction on the background of obesity with chronic kidney disease. *Georgian Medical News.* 2018; 10(283): 76-80. PMID: 30516498
9. Khukhlina OS, Antoniv AA, Kanovska LV, et al. The intensity of the antioxidant protection system and oxidative stress factors in patients with non-alcoholic steatohepatitis depending on the form of chronic kidney disease. *Georgian Medical News.* 2018; 3(276): 71-6.
10. Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. *Exp Biol Med (Maywood).* 2015; 240(6): 809-20. PMID: 25873078. PMCID: PMC4818965. doi: 10.1177/1535370215579161
11. Zhang X, Lerman LO. The metabolic syndrome and chronic kidney disease. *Transl Res.* 2017 May; 183: 14-25. PMID: 28025032. PMCID: PMC5393937. doi: 10.1016/j.trsl.2016.12.004
12. Zhao H, Song X, Li Z, Wang X. Risk factors associated with nonalcoholic fatty liver disease and fibrosis among patients with type 2 diabetes mellitus. *Medicine (Baltimore).* 2018; 97(37): e12356. PMID: 30212992. PMCID: PMC6156034. doi: 10.1097/MD.00000000000012356

*Antoniv A.A.,
Yurnyuk S.V.,
Kosar L.Yu.,
Chodura S.V.*

ВДНЗ України «Буковинський державний медичний університет»

ПАТОГЕНЕТИЧНІ ОСОБЛИВОСТІ ПЕРЕБІГУ НЕАЛКОГОЛЬНОЇ ЖИРОВОЇ ХВОРОБИ ПЕЧІНКИ ТА ХРОНІЧНОЇ ХВОРОБИ НИРОК

*Antoniv A.A.,
Yurnyuk S.V.,
Kosar L.Yu.,
Chodura S.V.*

Bukovynian State Medical University

PATHOGENETIC FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEASE AND CHRONIC KIDNEY DISEASE

Summary.

The study of fibrinolytic activity of blood showed that total fibrinolytic activity (TFA) of blood plasma in patients of all groups was significantly lower than the control indexes: in patients with NAS - by 7,1%, patients with NAS with CKD - by 14,9%, patients with NASH - by 17,2%, patients with NASH with CKD - by 18,9%, patients with CKD - by 10,6% (p <0,05) with the presence of a probable intergroup difference between groups with comorbidity and isolated course of CKD (p <0,05). The suppression of TFA occurred at the expense of the decrease of EF: in patients with NAS the index is significantly lower than the control in 1,2 times, in patients with NAS with CKD - in 1,4 times, in patients with NASH - in 1,7 times, in the group of patients with NASH and CKD - by 1,9 times, while in the group of patients with CKD, the suppression of EF was registered - 1,3 times (p <0,05). At the same time, the NEF in patients of all groups increased in comparison with the PHP group: in patients with NAS, in 1,2 times, in patients with NAS with CKD - in 1,3 times, in patients with NASH - in 1,4 times, in the group of patients with NASH with CKD - 1,5 times, while in the group of patients with CKD the activation of NEF was registered 1,2 times (p <0,05), with the presence of a probable difference between the groups with comorbidity and isolated course of CKD (p <0,05).

Анотація.

Дослідження фібринолітичної активності крові показало, що сумарна ферментативна активність (СФА) плазми крові у хворих усіх груп була вірогідно нижча від контрольних показників: у хворих на НАСП – на 7,1 %, хворих на НАСП із ХХН – на 14,9 %, хворих на НАСГ – на 17,2 %, хворих на НАСГ із ХХН – на 18,9 %, хворих на ХХН – на 10,6 % ($p < 0,05$) із наявністю вірогідної міжгрупової різниці між групами з коморбідністю та ізольованим перебігом ХХН ($p < 0,05$). Гальмування СФА відбувались за рахунок зниження ФФА: у хворих на НАСП показник вірогідно нижчим за контрольні у 1,2 рази, у хворих на НАСП із ХХН – у 1,4 рази, у хворих на НАСГ – у 1,7 рази, у групі хворих на НАСГ із ХХН – у 1,9 рази, у той час як у групі хворих на ХХН було зареєстровано пригнічення ферментативної фібринолітичної активності (ФФА) – у 1,3 рази ($p < 0,05$). Водночас, неферментативна фібринолітична активність (НФА) у хворих усіх груп зростала у порівнянні з групою практично здорових осіб (ПЗО): відповідно у хворих на НАСП – у 1,2 рази, у хворих на НАСП із ХХН – у 1,3 рази, у хворих на НАСГ – у 1,4 рази, у групі хворих на НАСГ із ХХН – у 1,5 рази, у той час як у групі хворих на ХХН було зареєстрована активація НФА – у 1,2 рази ($p < 0,05$), із наявністю вірогідної різниці між групами з коморбідністю та ізольованим перебігом ХХН ($p < 0,05$). Аналіз показників гемостазу та фібринолізу у обстежених хворих на НАСГ залежно від стадії ХХН показав, що із зростанням стадії ХХН активність зсідання зростає, за виключенням вмісту фібриногену (найбільш ймовірно внаслідок коагулопатії споживання), активність чинників протизсідуючої системи зменшується, сумарна та ферментативна активність фібринолізу знижуються, а неферментативна компенсаторно зростає. Таким чином, метаболічна інтоксикація, оксидативний стрес, які супроводжують перебіг НАЖХП за умов ожиріння та ХХН, сприяють активації калікреїн-кінінової системи, утворенню плазміну та тромбіну з подальшим порушенням рівноваги між ними, розвитку стазу, сладж-феномену, утворенням тромбоцитарних та еритроцитарних агрегатів у системі кровообігу. Наслідком значної активації гемокоагуляції на тлі пригнічення СФА є місцеве згортання крові в артеріях.

Keywords: *nonalcoholic fatty liver disease, chronic kidney disease, fibrinolytic activity.*

Ключові слова: *неалкогольна жирова хвороба печінки, хронічна хвороба нирок, фібринолітична активність*

Introduction. An important problem in internal medicine is the problem of the comorbidity of non-alcoholic fatty liver disease (NAFLD) with obesity and chronic kidney disease (CKD), which has a significant overall medical and social significance [1,2,3]. The comorbidity of non-alcoholic steatohepatitis (NASH) and chronic kidney disease (CKD) on the background of obesity is often recently drawn to the attention of both practitioners and researchers [1,2]. Schematically, the development of NASH can be presented in several stages: fatty infiltration of the liver, oxidative stress, mitochondrial dysfunction, TNF/endotoxin-mediated injury, aseptic inflammation, diffused liver fibrosis, development of liver-cellular insufficiency (LCI) [1,2,3]. The first place among the causes of the development of NASH is insulin resistance syndrome. NASH most often occurs in obesity (20-81%). The prevalence of NASH in the world is 10% (600 million people) [2,4]. In the last 5 years in Ukraine, the incidence of steatohepatitis has increased by 76.6%. In the 12-40% of patients with liver steatosis during 8-13 years, NASH develops with early liver fibrosis (LF). Chronic kidney disease (CKD) is an important problem in Ukraine and the world today, and the incidence rate has increased by 17% in recent years.

The frequency of occurrence of NASH in patients with CKD is unknown. The mechanisms of their joint development are described in isolated works, which were conducted mainly in the experiments [5,6,7,8]. Despite the fact that among various pathological processes in the internal organs that occur in the background of a metabolic syndrome - NASH is an extremely common disease, and quite often it occurs in patients with CKD, so far, this comorbidity remains a

significant problem of the present and needs to be sufficiently studied.

The purpose of the study: to determine the features of changes fibrinolytic activity of blood in patients with non-alcoholic fatty liver disease and chronic kidney disease.

Material and methods. 444 patients were examined: of which 84 patients with obesity grade I (group 1), which contained 2 subgroups: 32 patients with NAS and 52 patients with NASH; 270 patients with NAFLD with comorbid obesity of the I grade and CKD I-III stage (group 2), including 110 patients with NAS and 160 patients with NASH. The control group consisted of 90 patients with CKD of I-III stage with normal body weight (group 3). To determine the dependence of the NAFLD course on the form and stage of the CKD, the group of patients was randomized according to age, sex, degree of obesity, and activity of NASH.

Diagnosis of NAFLD was established in accordance with the unified clinical protocol approved by the order of the Ministry of Health of Ukraine No.826 dated on November 6, 2014, in the presence of criteria for the exclusion of chronic diffuse liver disease of the viral, hereditary, autoimmune or drugs origin as causes of cholestatic or cytolytic syndromes, as well the results of ultrasonographic (USG) examination and morphological examination of liver. Diagnosis and treatment of CKD were performed in accordance with the recommendations of the clinical guidelines of the State Institute "Institute of Nephrology, NAMS of Ukraine" (2012). The study included patients with CKD I-III stage without a nephrotic syndrome with chronic complicated pyelonephritis in the phase of exacerbation decrease or with a latent course.

The total coagulation potential of blood (prothrombin time (PT)), plasma fibrinolytic activity, plasminogen potential activity (PPA), fibrinogen level in blood plasma, activity of antithrombin III (AT III), activity of XIII factor were studied using the sets of reagents of the company "Simko Ltd" (m Lviv) according to the methods of N. Titsa. Using the reagents of the same company, we studied the state of enzymatic (EFS) and non-enzymatic fibrinolysis (NEF) in blood plasma. The principle of the method is that when azofibrin is incubated with a standard amount of plasminogen in the presence of fibrinolysis activators that are contained in blood plasma, plasmin is formed, whose activity is estimated by the degree of coloring of the solution in alkaline medium in the presence of E-amino-capronic acid (EF) or without (NEF). The difference between them determines the state of the EFS. By the same method, but without the use of plasminogen and E-amino-capronic acid, the proteolytic activity of blood plasma was determined using azoalbumin, azocasein, azocol (Simko Ltd, Lviv), and the total activity of proteinases by M. Kunitz.

Statistical processing of the results of the research was carried out using parametric and nonparametric methods of variation statistics. The normal distribution was checked using the Shapiro-Uilka test and the method of direct visual evaluation of eigenvalues distribution histograms. Quantitative indices having a normal distribution are represented as mean (M) ± standard

deviation (S). In a nonparametric distribution, the data is presented as median (Me) as position, upper (Q75) and lower quartile (Q25) as a measure of scattering. For comparisons of data that had a normal distribution pattern, parametric tests were used to estimate the Student's t-criterion, Fisher's F-criterion. To estimate the degree of dependence between variables, Pearson correlation analysis using parametric distribution and Spearman rank correlation coefficient were used. To compare discrete values in independent groups, the criterion χ^2 of maximum probability (log-likelihood) (MP χ^2) was used; for calculating the pairs of discrete values, the calculation of the modification of Fisher's exact criterion (mid-p) was used. The evaluation of treatment efficacy was based on the effects of treatment, absolute (AR) and relative (RR) therapeutic effects, therapeutic benefits - absolute risk difference (ARR), relative risk changes (RRR), as well as odds ratios (ORs), calculated confidence intervals and the criterion of reliability for RR and OR. Statistica for Windows version 8.0 (Stat Soft inc., USA), Microsoft Excel 2007 (Microsoft, USA) software packages were used for statistical and graphical analysis of the obtained results.

Results and discussion. Analysis of the results of the 2nd phase of the coagulation hemostasis showed that the PT was significantly lowered in patients of all groups of observation (Table 1).

Table 1

Indicators of hemostasis and fibrinolysis in patients with non-alcoholic liver steatosis and steatohepatitis depending on comorbidity with CKD (M ± m)

Indicators, units measurement	PHP, n=30	Groups of patients examined				
		NAS, n=32	NAS, CKD, n=110	NASH, n=52	NASH,CKD, n=160	CKD, n=90
PT, sec.	22,12±0,46	18,41±0,32*	15,73±0,23*/**	13,56±0,21*/**	11,38±0,25*/**/#	16,37±0,29*/**/##
Fibrinogen, g/l	3,81±0,12	3,38±0,15*	3,15±0,11*	2,69±0,17*/**	1,87±0,10*/**/#	4,35±0,09*/**/##
TT, sec	16,95±0,87	15,75±0,36	12,31±0,27*/**	11,84±0,23*/**	10,25±0,15*/**/#	13,27±0,20*/**/##
AT III, %	95,48±2,01	82,81±3,18*	78,33±3,21*	73,38±2,86*	67,27±2,24*/**	80,27±3,28*/**
Total fibrinolytic activity (TFA), E440/ml/hour	1,69±0,02	1,58±0,02*	1,47±0,01*	1,40±0,01*/**	1,37±0,004*/**/#	1,52±0,01*/**/##
Non-enzymatic fibrinolytic activity (NFA), E440/ml/hour	0,49±0,02	0,60±0,01*	0,63±0,003*	0,69±0,004*/**	0,75±0,01*/**/#	0,57±0,002*/**/##
Enzymatic fibrinolytic activity (EFA), E440/ml/hour	1,20±0,01	0,98±0,01*	0,84±0,01*/**	0,71±0,004*/**	0,62±0,01*/**/#	0,95±0,01*/**/##
Hageman-dependent fibrinolysis, min.	19,45±0,19	22,52±1,33*	30,21±1,18*/**	34,53±1,15*/**	37,31±1,28*/**	29,39±1,07*/**
XIII Factor, %	99,91±2,45	97,32±2,41	82,43±1,12*	70,82±1,13*/**	68,18±1,29*/**	80,25±2,34*/**
potential plasminogen-activating activity, min.	15,23±0,27	18,31±0,21*	22,20±0,18*/**	26,38±0,13*/**	30,15±0,12*/**/#	24,01±0,11*/**/##

Notes: * - the difference is probable compared to the indicator in the PHP ($p < 0,05$);

** - the difference is probable in comparison with the indicator in patients with NAS ($p < 0,05$);

*** - the difference is probable compared with the index in patients with NASH ($p < 0,05$);

- the difference is probable in comparison with the index in patients with NAS with CKD ($p < 0,05$); ## - the difference is probable compared with the index in patients with NASH with CKD ($p < 0,05$).

The maximum decrease in the rate was observed in patients with NASH and CKD - 1.9 times compared with the indicator in the PHPs ($p < 0.05$) with the presence of intergroup difference; in patients with NASH without CKD, PT was 1.6 times lower than that in practical healthy person (PHPs) ($p < 0.05$). In patients with NAS, less intensive changes were observed: PT in the group without comorbidity was 1.2 times lower ($P < 0.05$), in patients with NAS with CKD - 1.4 times ($p < 0.05$). In patients with isolated CKD, the decrease in PT was 1.4 times ($p < 0.05$) (Table 1). The study of the 3rd phase of coagulation hemostasis suggests that in patients the content of fibrinogen in the blood was reduced: in patients with NASH and NASH with CKD - respectively, in 1,4 and 2,0 times ($p < 0,05$) against growth in 1, 2 times in patients with isolated CKD ($p < 0.05$); in patients with NAS - the decrease was 12.7% and 17.1% ($p < 0.05$), the indicator was significantly different in comparison with the intergroup aspect ($p < 0.05$). Reducing the fibrinogen content in the blood of patients with NAFLD with CKD and obesity suggests a lack of synthesis of Factor I of coagulation in the liver and / or activation of the hemostasis system in response to inflammation, the development of hypercoagulation, the formation of microthrombus and the addition of a certain amount of fibrinogen in this process. Registration of low content of fibrinogen in patients with obesity and obesity is indicative of the development of coagulopathy of consumption, that is, the use of fibrinogen in the processes of intravascular blood coagulation with the simultaneous exhaustion of the circulating pool of this factor. At the same time, the increase in the fibrinogen content in patients with CKD without comorbid pathology indicates activation of blood clotting due to chronic inflammation.

Changes in the activity of AT III (Table 1) indicate an insufficiency of the anticoagulation potential of the blood. In particular, the inhibition of AT III activity in all groups of comparison with the maximum inhibition of patients with NASH with CKD was determined 1.4 times ($p < 0.05$) versus a decrease of 1.3 times in patients with NASH (Table 1). In the groups of patients with NAS and NAS with CKD, a moderate difference was not established. It should also be noted that in patients with CKD without comorbid conditions, the activity of AT III was significantly reduced by 1.2 times ($p < 0.05$).

The study of fibrinolytic activity of blood showed that TFA of blood plasma in patients of all groups was significantly lower than the control indexes: in patients with NAS - by 7,1%, patients with NAS with CKD - by 14,9%, patients with NASH - by 17,2%, patients with NASH with CKD - by 18,9%, patients with CKD - by 10,6% ($p < 0.05$) with the presence of a probable intergroup difference between groups with comorbidity and isolated course of CKD ($p < 0, 05$). The suppression of TFA occurred at the expense of the decrease of EFA: in patients with NAS the index is significantly lower than the control in 1,2 times, in patients with NAS with CKD - in 1,4 times, in patients with NASH - in 1,7 times, in the group of patients with NASH and CKD - by 1.9 times, while in the group of patients with CKD, the suppression of EFA was registered - 1,3 times ($p < 0,05$).

At the same time, the NFA in patients of all groups increased in comparison with the PHP group: in patients with NAS, in 1,2 times, in patients with NAS with CKD - in 1,3 times, in patients with NASH - in 1,4 times, in the group of patients with NASH with CKD - 1.5 times, while in the group of patients with CKD the activation of NFA was registered 1.2 times ($p < 0.05$), with the presence of a probable difference between the groups with comorbidity and isolated course of CKD ($p < 0.05$). That is, at patients with NASH with CKD NFA acquired compensatory maximum intensity ($p < 0,05$). At the same time, there was a probable decrease in the activity of Hageman-dependent fibrinolysis: respectively, in patients with NAS - 1.2 times, in patients with NAS and CKD - 1.6 times, in patients with NASH - 1.8 times, in the group patients with NASH with CKD - 1.9 times, while in the group of patients with CKD decrease in Hageman-dependent fibrinolysis activity was 1.5 times ($p < 0.05$) with the probable difference between groups with comorbidity and isolated flow of CKD ($p < 0.05$). The activity of the fibrin stabilizing factor in patients with NASH and NASH with CKD decreased respectively by 1.4 and 1.5 times ($p < 0.05$), indicating a violation of the postcoagulation phase of blood coagulation. In groups of patients with NAS - changes were unlikely, and in patients with NAS with CKD and isolated CKD - reduction was 1.2 times ($p < 0.05$) (Table 1).

Patients with CKD had a probable reduction in PPA: in patients with NAS - 1.2 times, patients with NAS with CKD - 1.5 times, patients with NASH - 1.7 times, patients with NASH with CKD - in 2.0 times, in the group with CKD without comorbidity - the decrease was 1.6 times ($p < 0.05$) with the presence of a probable difference between the groups with comorbidity and the isolated course of CKD ($p < 0.05$) (Table 1).

Analysis of hemostasis and fibrinolysis indices in examined patients with NASH, depending on the stage of CKD showed that with the growth of the CKD stage, the activity of the cohort increases, with the exception of the fibrinogen content (most likely due to consumption coagulopathy), the activity of the anti-coagulation factors decreases, the total and enzymatic activity of fibrinolysis is reduced, and non-enzymatic compensator increases. Thus, metabolic intoxication, oxidative stress, which accompany the flow of NAFLD with obesity and CKD, promote the activation of the kallikrein-kinin system, the formation of plasma and thrombin, with subsequent disturbance of equilibrium between them, the development of stasis, slag phenomenon, the formation of platelet and erythrocytic aggregates in blood circulation system. The consequence of significant activation of hemocoagulation against the suppression of TFA is the local clotting of blood in the arteries. The function of Hageman-dependent fibrinolysis is the regular deprivation of the circulatory system from fibrin clots formed under conditions of inflammation. The results of our study indicate a decrease in the rate of enzymatic, Hageman-dependent fibrinolysis, which causes the compensatory activation of NEF. Slowdown of blood circulation in the liver and kidneys due to the formation of microthrombi in the microcirculatory sys-

tem promotes progression of hypoxia, formation of reactive oxygen species (ROS) and free radicals with subsequent damage to cellular membranes of hepatocytes, cytolysis, reduction of glomerular filtration rate (GFR) and closure of the "vicious" circle of the progression pathogenesis of NAFLD and CKD.

Conclusions. The role of chronic inflammation in CKD in the formation of hemostasis disorders and in the pathogenesis of progression of NASH on the background of obesity, which in general can be characterized as hypercoagulation syndrome due to significant inhibition of anti-coagulation factors and fibrinolytic systems and activation of plasma coagulation factors (fibrinogen) due to chronic inflammation.

The prospect of further scientific research in this direction is the development of a method for correction of hemostasis and fibrinolysis indices in patients with NAFLD depending on the stage of CKD.

References

1. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. *Acriticalappraisal. J. Hepatol.* 2013;58:1007-109.
2. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. *Obesity Reviews.* 2010;

11(6): 430-445.

3. Chang Y, Ryu S, Sung E, et al. [Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men.] *Metabolism.* 2008. 57: 569–576.

4. Machado MV, Gonçalves S, Carepa F, et al. [Impaired renal function in morbid obesity patients with nonalcoholic fatty liver disease.] *Liver Int.* 2012. Feb; 32(2): 241-248.

5. Marcuccilli M, Choncho M. [NAFLD and Chronic Kidney Disease]. *Int. J. Mol. Sci.* 2016. Apr; 17(4): 562.

6. Musso G, Cassader M, Cohny S, et al. [Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities.] *Diabetes Care.* 2016. Oct; 39(10): 1830-1845.

7. Papademetriou M, Athyros VG, Geladari E, et al. [The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?] *Current Vascular Pharmacology,* 2017;15:1-15.

8. KDIGO 2012[Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.] *Kidney International Supplement* 2013;3:1–150.

УДК 616.311.2-002+616-006.66:-008.1

Доктор медичних наук, Державна установа «Інститут стоматології та щелепно-лицьової хірургії Національної академії медичних наук України»

Бабеня Г.О.

кандидат медичних наук, Державна установа «Інститут стоматології та щелепно-лицьової хірургії Національної академії медичних наук України»

Гінжул І.В.²

кандидат медичних наук, Медичний центр «Headline»

Христова М.Т.

кандидат медичних наук, Одеський національний медичний університет МОЗ України

DOI: 10.24412/2520-2480-2020-3486-57-65

ОЦІНКА ЕФЕКТИВНОСТІ КОМПЛЕКСНОГО ЛІКУВАННЯ ГЕНЕРАЛІЗОВАНОГО ПАРОДОНТИТУ У ЖІНОК ПІСЛЯ ПРОВЕДЕНОЇ ХІМІОТЕРАПІЇ З ПРИВОДУ РАКУ МОЛОЧНОЇ ЗАЛОЗИ У ВІДДАЛЕНИЙ ТЕРМІН СПОСТЕРЕЖЕННЯ

Skyba V.Ya.

doctor of medicine, State Establishment "The Institute of Stomatology and Maxillo-Facial Surgery National Academy of Medical Sciences of Ukraine"

Babenia G.O.

candidate of medical Sciences, State Establishment "The Institute of Stomatology and Maxillo-Facial Surgery National Academy of Medical Sciences of Ukraine"

Ginzul I.V.²

candidate of medical Sciences, Medical Center «Headline»

Khristova M.T.

candidate of medical Sciences, Odesa National Medical University of the Ministry of Health of Ukraine

EVALUATION OF THE EFFECTIVENESS OF COMPLEX TREATMENT OF GENERALIZED PERIODONTITIS IN WOMEN AFTER CHEMOTHERAPY FOR BREAST CANCER IN THE LONG-TERM

Анотація.

У статті наведено результати комплексного лікування генералізованого пародонтиту у жінок після проведеної хіміотерапії з приводу раку молочної залози у віддалений термін (через 6 місяців).

Доведено, що застосування запропонованого лікування генералізованого пародонтиту у жінок даної категорії дозволило зменшити кількість скарг хворих, сприяло покращенню гігієнічного стану порожнини рота,